SG Americas Securities LLC Buys Shares of 24,417 Poseida Therapeutics, Inc. (NASDAQ:PSTX)

SG Americas Securities LLC bought a new position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 24,417 shares of the company’s stock, valued at approximately $70,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Bayesian Capital Management LP acquired a new position in Poseida Therapeutics during the 1st quarter worth approximately $33,000. Marshall Wace LLP acquired a new position in shares of Poseida Therapeutics during the second quarter worth $31,000. Rothschild Investment LLC bought a new position in shares of Poseida Therapeutics in the 2nd quarter valued at $35,000. Principal Financial Group Inc. acquired a new stake in shares of Poseida Therapeutics during the 2nd quarter valued at $35,000. Finally, Mackenzie Financial Corp bought a new stake in Poseida Therapeutics during the 2nd quarter worth $51,000. Institutional investors own 46.87% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Poseida Therapeutics in a research report on Thursday, October 17th.

Poseida Therapeutics Stock Up 2.9 %

NASDAQ:PSTX opened at $2.48 on Tuesday. Poseida Therapeutics, Inc. has a one year low of $1.83 and a one year high of $4.27. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.48 and a quick ratio of 2.48. The company has a market cap of $240.88 million, a PE ratio of -2.08 and a beta of 0.51. The firm’s 50 day simple moving average is $2.79 and its 200 day simple moving average is $2.86.

Poseida Therapeutics (NASDAQ:PSTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. The company had revenue of $25.97 million for the quarter, compared to analyst estimates of $13.75 million. On average, research analysts anticipate that Poseida Therapeutics, Inc. will post -1.57 earnings per share for the current year.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.